SK1332000A3 - A pharmaceutical composition active in reducing production of mcp-1 protein - Google Patents

A pharmaceutical composition active in reducing production of mcp-1 protein Download PDF

Info

Publication number: SK1332000A3
Authority: SK; Slovakia
Prior art keywords: mcp; protein; pharmaceutical composition; production; disorders
Prior art date: 1997-07-28

Application number

SK133-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Angelo Guglielmotti

Claudio Milanese

Original Assignee

Acraf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-28

Filing date

1998-07-22

Publication date

2000-12-11

1998-07-22 Application filed by Acraf filed Critical Acraf

2000-12-11 Publication of SK1332000A3 publication Critical patent/SK1332000A3/sk

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 title 1
102100021943 C-C motif chemokine 2 Human genes 0.000 claims abstract description 22
101710155857 C-C motif chemokine 2 Proteins 0.000 claims abstract description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
208000035475 disorder Diseases 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 9
150000001875 compounds Chemical class 0.000 claims abstract description 8
150000007529 inorganic bases Chemical class 0.000 claims abstract description 3
150000007530 organic bases Chemical class 0.000 claims abstract description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 6
206010047115 Vasculitis Diseases 0.000 claims description 5
208000019693 Lung disease Diseases 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
208000035965 Postoperative Complications Diseases 0.000 claims description 3
238000013130 cardiovascular surgery Methods 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
239000007943 implant Substances 0.000 claims description 2
239000003814 drug Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
230000000694 effects Effects 0.000 description 7
102000019034 Chemokines Human genes 0.000 description 6
108010012236 Chemokines Proteins 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
210000001616 monocyte Anatomy 0.000 description 5
208000017169 kidney disease Diseases 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
238000000034 method Methods 0.000 description 4
230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
230000006378 damage Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
229920006008 lipopolysaccharide Polymers 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000002792 vascular Effects 0.000 description 3
241001135755 Betaproteobacteria Species 0.000 description 2
102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108010055204 Chemokine CCL8 Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
208000029523 Interstitial Lung disease Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000003399 chemotactic effect Effects 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
150000001945 cysteines Chemical class 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000002085 irritant Substances 0.000 description 2
231100000021 irritant Toxicity 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000203 mixture Substances 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
-1 MIP-1a and ΜΙΡ-1β Proteins 0.000 description 1
206010065673 Nephritic syndrome Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000036778 atheroma formation Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
108700027921 interferon tau Proteins 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000014616 translation Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

SK133-2000A 1997-07-28 1998-07-22 A pharmaceutical composition active in reducing production of mcp-1 protein SK1332000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT97MI001788A IT1293794B1 (it)	1997-07-28	1997-07-28	Farmaco attivo nel ridurre la produzione di proteina mcp-1
PCT/EP1998/004925 WO1999004791A1 (fr)	1997-07-28	1998-07-22	Composition pharmaceutique active dans la reduction de la production de proteine mcp-1

Publications (1)

Publication Number	Publication Date
SK1332000A3 true SK1332000A3 (en)	2000-12-11

Family

ID=11377641

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK133-2000A SK1332000A3 (en)	1997-07-28	1998-07-22	A pharmaceutical composition active in reducing production of mcp-1 protein

Country Status (15)

Country	Link
US (1)	US6191158B1 (fr)
EP (1)	EP0999836A1 (fr)
JP (1)	JP2001510802A (fr)
KR (1)	KR20010022333A (fr)
CN (1)	CN1265592A (fr)
AU (1)	AU9160298A (fr)
BG (1)	BG104162A (fr)
CA (1)	CA2298507A1 (fr)
EA (1)	EA200000168A1 (fr)
HU (1)	HUP0004936A3 (fr)
IL (1)	IL134050A0 (fr)
IT (1)	IT1293794B1 (fr)
SK (1)	SK1332000A3 (fr)
TR (1)	TR200000244T2 (fr)
WO (1)	WO1999004791A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7238711B1 (en)	1999-03-17	2007-07-03	Cambridge University Technical Services Ltd.	Compounds and methods to inhibit or augment an inflammatory response
ITMI20062254A1 (it)	2006-11-24	2008-05-25	Acraf	Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3970194A (en) *	1975-01-08	1976-07-20	Philip Morris Incorporated	Razor blade cartridge and display article
IT1147079B (it) *	1980-05-30	1986-11-19	Sigma Tau Ind Farmacuetiche Ri	Esteri di alcossi-acil derivati della carnitina procedimento per la loro preparatione e composizioni farmaceutiche che li contengono
IT1131779B (it) *	1980-07-29	1986-06-25	Acraf	Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1189052B (it) *	1981-11-27	1988-01-28	Acraf	Trattamento della cataratta
IT1197805B (it) *	1986-08-01	1988-12-06	Acraf	Metodo per il tratamento di lenti a contatto

1997
- 1997-07-28 IT IT97MI001788A patent/IT1293794B1/it active IP Right Grant
1998
- 1998-07-22 US US09/463,665 patent/US6191158B1/en not_active Expired - Fee Related
- 1998-07-22 CA CA002298507A patent/CA2298507A1/fr not_active Abandoned
- 1998-07-22 SK SK133-2000A patent/SK1332000A3/sk unknown
- 1998-07-22 KR KR1020007000912A patent/KR20010022333A/ko not_active Withdrawn
- 1998-07-22 EA EA200000168A patent/EA200000168A1/ru unknown
- 1998-07-22 CN CN98807694A patent/CN1265592A/zh active Pending
- 1998-07-22 AU AU91602/98A patent/AU9160298A/en not_active Abandoned
- 1998-07-22 WO PCT/EP1998/004925 patent/WO1999004791A1/fr not_active Application Discontinuation
- 1998-07-22 JP JP2000503846A patent/JP2001510802A/ja active Pending
- 1998-07-22 HU HU0004936A patent/HUP0004936A3/hu unknown
- 1998-07-22 EP EP98943863A patent/EP0999836A1/fr not_active Withdrawn
- 1998-07-22 IL IL13405098A patent/IL134050A0/xx unknown
- 1998-07-22 TR TR2000/00244T patent/TR200000244T2/xx unknown
2000
- 2000-02-17 BG BG104162A patent/BG104162A/xx unknown

Also Published As

Publication number	Publication date
IT1293794B1 (it)	1999-03-10
ITMI971788A1 (it)	1999-01-28
IL134050A0 (en)	2001-04-30
BG104162A (en)	2000-12-29
HUP0004936A3 (en)	2002-01-28
US6191158B1 (en)	2001-02-20
CA2298507A1 (fr)	1999-02-04
JP2001510802A (ja)	2001-08-07
KR20010022333A (ko)	2001-03-15
CN1265592A (zh)	2000-09-06
EA200000168A1 (ru)	2000-08-28
AU9160298A (en)	1999-02-16
WO1999004791A1 (fr)	1999-02-04
HUP0004936A2 (hu)	2001-11-28
EP0999836A1 (fr)	2000-05-17
TR200000244T2 (tr)	2000-09-21

Publication	Publication Date	Title
Wallace	1974	Colchicine
RU2460526C2 (ru)	2012-09-10	Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна
CA2456533A1 (fr)	2003-02-20	Derives de l'acide hydroxamique inhibiteurs de l'enzyme histone deacetylase utilises comme nouveaux medicaments anti-inflammatoires inhibiteurs de la synthese de la cytokine
PT1201241E (pt)	2010-12-02	Composições contendo capsaicina ou análogos de capsaicina e um anestésico
AU744492B2 (en)	2002-02-28	A pharmaceutical composition active in reducing production of mcp-1 protein
BG65681B1 (bg)	2009-06-30	Средство за лечение на болести на ставите
HU219482B (hu)	2001-04-28	(+)Doxazoszin alkalmazása vizeletfolyást fokozó gyógyászati készítmények előállítására
US5547971A (en)	1996-08-20	Use of leflunomide for inhibiting interleukin 8
KR101318806B1 (ko)	2013-10-16	메틸페니데이트 유도체 및 그 용도
JP2003081838A (ja)	2003-03-19	グルコサミン製剤
SK1332000A3 (en)	2000-12-11	A pharmaceutical composition active in reducing production of mcp-1 protein
KR100310665B1 (ko)	2001-12-28	피부질환치료용약제학적조성물
AU2020241731B2 (en)	2023-09-07	Use of GABAA receptor modulators for treatment of pain
JPS62167725A (ja)	1987-07-24	卒中治療剤
WO2000057914A1 (fr)	2000-10-05	Agents permettant d'abaisser la tension oculaire
US6706767B2 (en)	2004-03-16	Therapeutics for chemokine mediated diseases
JP4381495B2 (ja)	2009-12-09	有機ゲルマニウム化合物を有効成分とするｍｃｐ−１受容体拮抗剤、及びｍｃｐ−１が関与する炎症性疾患及び臓器障害の発症予防または治療剤
EP1203583B1 (fr)	2005-12-07	Remedes contre la polyarthrite rhumatoide
JP3587851B2 (ja)	2004-11-10	Ｔｎｆ誘発病状の治療におけるベンジダミンの使用
MXPA00001003A (en)	2001-05-07	A pharmaceutical composition active in reducing production of mcp-1 protein
CZ2000292A3 (cs)	2000-10-11	Farmaceutický prostředek aktivní při snižování produkce proteinu MCP-1
WO2002045702A2 (fr)	2002-06-13	Traitement des maladies induites par les chimiokines
JPH05194217A (ja)	1993-08-03	抗高血圧組み合わせ医薬
Shufflebarger et al.	1996	The effect of ketorolac on microvascular thrombosis in an experimental rabbit model
EP1733723B1 (fr)	2011-07-13	Medicament capable d'inhiber l'activation du facteur de transcription klf5